This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Marjolein van Egmond, Ph.D.
Professor of Oncology and Inflammation at Amsterdam University Medical Center


Prof.dr. Marjolein van Egmond received her Ph.D. from University Medical Center Utrecht, The Netherlands in 2000 (under supervision of Prof. Dr. J.G.J. van de Winkel). Her thesis focussed on the identification the function of the human Fc receptor for immunoglobulin A (FcαRI). Since FcαRI was identified as potential target for tumour therapy, the focus of the research shifted during a short post-doc period at Medarex Europe towards FcαRI-induced antibody-mediated tumour killing by immune cells.

After her transfer to the VU Medical Center in 2000, she started her own research group, which studies antibody activation of innate myeloid immune cells, macrophages and neutrophils, with emphasis on understanding the role of immunoglobulin A (IgA) in physiology and pathology.  Her research focuses specifically on (1) the contribution of abnormal antibody responses to chronic inflammation and autoimmunity and (2) monoclonal antibody therapy of cancer. Dr. van Egmond’s research is highly translational and she has a cross appointment with the Department of Surgery and the Department of Molecular Cell Biology and Immunology, to facilitate the rapid progression of pre-clinical findings into clinical applications.

In 2005 Dr. van Egmond was appointed as assistant professor, followed by an appointment as associated professor in 2008. In 2014 she was appointed as Professor of  ‘Oncology and Inflammation’, and received a Fenna Diemer-Lindeboom chair. Prof.dr. van Egmond received several prestigious personal grants of the Netherlands Organization for Scientific Research (NWO). In 2016 she received the Young investigator award for basic/translational research of the European Society of Clinical Investigations.

Agenda Sessions

  • Immunoglobulin A: Trojan Horse or Magic Bullet?